Company intelligence / Profile preview

Biofrontera

Woburn, Massachusetts, United Statesbiofrontera-us.com ↗

Ownership: Public · BFRI
Development stage: Commercial

Overview

Biofrontera has commercial products including Ameluz (a topical prescription drug) and RhodoLED/RhodoLED XL (proprietary red-light lamps) for photodynamic therapy of actinic keratoses. The company reported record financial results for fiscal year 2024 and is conducting clinical trials to expand indications to include trunk and extremities, non-melanoma skin cancers, and acne.

Therapeutic areas: DermatologyInfectious Diseases
Modalities: Photodynamic therapy (PDT)Topical antibioticsNanoemulsion technology
Industry: Biotech

Drug pipeline

7 assets

aminolevulinic acid

Approved

6 more assets in the full pipeline.

Request access →

Partnerships

LEO Pharma GmbHGerman Medical Engineering GmbH

Financials

Market cap: $20M
Total revenue: $12M
Enterprise value: $22.8M

Beyond the preview

Go deeper on Biofrontera.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Biofrontera.

Explore the full profile